Delay in surgical treatment of patients with hilar cholangiocarcinoma: does time impact outcomes?. Issue 5 (26th August 2013)
- Record Type:
- Journal Article
- Title:
- Delay in surgical treatment of patients with hilar cholangiocarcinoma: does time impact outcomes?. Issue 5 (26th August 2013)
- Main Title:
- Delay in surgical treatment of patients with hilar cholangiocarcinoma: does time impact outcomes?
- Authors:
- Ruys, Anthony T.
Heuts, Simon G.
Rauws, Eric A.
Busch, Olivier R. C.
Gouma, Dirk J.
van, Thomas M. - Abstract:
- <abstract abstract-type="main"> <title>Abstract</title> <sec id="hpb12156-sec-0001" sec-type="section"> <title>Background</title> <p>Substantial time elapses before patients with hilar cholangiocarcinoma (HCC) receive surgical treatment because of time‐consuming preoperative staging and other interventions, including biliary drainage and portal vein embolization. Prolonged times potentially lead to unresectability and the formation of metastases, yet these issues have not been investigated previously in HCC. This study aimed to evaluate the time between onset of symptoms and the provision of ultimate treatment in patients with HCC and the impact of the length of time on outcomes.</p> </sec> <sec id="hpb12156-sec-0002" sec-type="section"> <title>Methods</title> <p>Delays in the treatment of consecutive patients with HCC were evaluated by contacting general practitioners (GPs) and extracting data from hospital files. Time periods were correlated with resectability, occurrence of metastasis, tumour stage and survival using logistic and Cox regression analyses.</p> </sec> <sec id="hpb12156-sec-0003" sec-type="section"> <title>Results</title> <p>Treatment times in 209 consecutive HCC patients were evaluated. The median time from first GP visit until presentation at the tertiary centre was 35 days. Time until treatment was longer when initial symptoms did not include jaundice (non‐specific symptoms, <italic>P</italic> &lt; 0.001). Duration of workup and preoperative biliary<abstract abstract-type="main"> <title>Abstract</title> <sec id="hpb12156-sec-0001" sec-type="section"> <title>Background</title> <p>Substantial time elapses before patients with hilar cholangiocarcinoma (HCC) receive surgical treatment because of time‐consuming preoperative staging and other interventions, including biliary drainage and portal vein embolization. Prolonged times potentially lead to unresectability and the formation of metastases, yet these issues have not been investigated previously in HCC. This study aimed to evaluate the time between onset of symptoms and the provision of ultimate treatment in patients with HCC and the impact of the length of time on outcomes.</p> </sec> <sec id="hpb12156-sec-0002" sec-type="section"> <title>Methods</title> <p>Delays in the treatment of consecutive patients with HCC were evaluated by contacting general practitioners (GPs) and extracting data from hospital files. Time periods were correlated with resectability, occurrence of metastasis, tumour stage and survival using logistic and Cox regression analyses.</p> </sec> <sec id="hpb12156-sec-0003" sec-type="section"> <title>Results</title> <p>Treatment times in 209 consecutive HCC patients were evaluated. The median time from first GP visit until presentation at the tertiary centre was 35 days. Time until treatment was longer when initial symptoms did not include jaundice (non‐specific symptoms, <italic>P</italic> &lt; 0.001). Duration of workup and preoperative biliary drainage at the tertiary centre prior to final surgical treatment resulted in an additional median time of 74 days. No correlation was found between treatment time in weeks and resectability [odds ratio (OR) 1.010, 95% confidence interval (CI) 0.985–1.036], metastasis (OR = 0.947, 95% CI 0.897–1.000), tumour stage (OR = 1.006, 95% CI 0.981–1.031) or survival in resected patients (hazard ratio = 0.996, 95% CI 0.975–1.018).</p> </sec> <sec id="hpb12156-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The time that elapses between the presentation of symptoms and final treatment in patients with HCC is substantial, especially in patients with non‐specific symptoms. This time, however, does not affect resectability, metastasis, tumour stage or survival, which suggests that preoperative optimization should not be omitted because of potential delays in treatment.</p> </sec> </abstract> … (more)
- Is Part Of:
- HPB. Volume 16:Issue 5(2014:May)
- Journal:
- HPB
- Issue:
- Volume 16:Issue 5(2014:May)
- Issue Display:
- Volume 16, Issue 5 (2014)
- Year:
- 2014
- Volume:
- 16
- Issue:
- 5
- Issue Sort Value:
- 2014-0016-0005-0000
- Page Start:
- 469
- Page End:
- 474
- Publication Date:
- 2013-08-26
- Subjects:
- Liver -- Diseases -- Periodicals
Biliary tract -- Diseases -- Periodicals
Pancreas -- Diseases -- Periodicals
616.362005 - Journal URLs:
- https://www.journals.elsevier.com/hpb/ ↗
http://www.hpbonline.org/current ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1477-2574 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/hpb.12156 ↗
- Languages:
- English
- ISSNs:
- 1365-182X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4335.262340
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4296.xml